Aflibercept 8 mg in Polypoidal Choroidal Vasculopathy

This secondary analysis of the Study of the Effects of High-Dose Aflibercept Injected Into the Eye of Patients With an Age-Related Disorder That Causes Loss of Vision Due to Growth of Abnormal Blood Vessels at the Back of the Eye (PULSAR) randomized clinical trial investigates the efficacy and safety of aflibercept 8 mg vs aflibercept 2 mg in participants with indocyanine green angiography–confirmed polypoidal choroidal vasculopathy.